Publications by authors named "Heather P Becker"
Article Synopsis
- The study aimed to compare the efficacy and toxicity of paclitaxel (T) versus doxorubicin and cyclophosphamide (AC) in early-stage breast cancer patients.
- With 3,871 participants followed for about 6.1 years, results showed that T was not noninferior to AC in terms of relapse-free survival, and AC had a slight advantage in overall survival.
- Although T was associated with less toxicity, especially regarding hematologic issues, the findings indicate that AC is more effective.
Purpose: The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also sought to determine whether paclitaxel (T) is as efficacious as doxorubicin/cyclophosphamide (AC), but with reduced toxicity.
View Article and Find Full Text PDFBackground: Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older.
Methods: We randomly assigned patients with stage I, II, IIIA, or IIIB breast cancer to standard chemotherapy (either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin) or capecitabine.